D1 and D2 trials compared guselkumab vs placebo in patients with active PsA, with the major difference between the two being that only biologic-naïve patients were enrolled in the D2 trial. Today, we discuss three abstracts presented at ACR 2021 that expand on that work with an additional year of data.
All News
Article
Article
The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.
Dr. Antoni Chan
Tweet
PsA impacts many aspects of life. PRO such as VAS pain
and HAQ, are commonly assessed. The FACIT-Fatigue scale, ranked the highest by
patients. Personalized discussion is vital in assessment and shared decision making @RheumNow #ACR21 Abst#0751 https://t.co/gRfYK4sHc6 https://t.co/f5xjUnXsGQ
Dr. Antoni Chan
Tweet
With Deucravacitinib, a TYK2 inhibitor vs placebo, PsAID-12 and PsAID-9 scores were significantly improved
versus baseline at Week 16
and other PROs showing a clear improvement in PsA-related impact @RheumNow #ACR21 Abst#0750 https://t.co/JbeSE2dO94 https://t.co/pH79dXCYSs
🌞😎🍣 Vitamin D and Omega-3 FA ⬇️ Risk of developing autoimmune disease
1st prospective, randomized, double blind, placebo controlled trial
Vit D 2000IU and/or Omega 3-FA 1000mg ⬇️autoimmune disease by 25-30%
#ACR21 #ACRBest @RheumNow
Abs#957
https://t.co/7dODuplg7e https://t.co/GUKhYXbSXU
Pedro Castillo
Tweet
Awesome presentation today from Dr. Cristina Ruiz-Romero on lipidomic profiles in RA vs PsA. Using mass spectrometry, found differences in both synovial bx and fluid. Potentially useful lipid markers, more studies to follow.
#ACR21 #ACRBest Abst#0946 @RheumNow https://t.co/KmWCPKijSx
Pedro Castillo
Tweet
Interesting study with Dr. Julia Manasson on gut and skin microbiome in monozygotic twins discordant for psoriatic disease. (red = Psoriatic). Gut ruminococcus bromii virtually absent in psoriatic pts. Eager to see further studies!
#ACR21 Abst#0944 @RheumNow https://t.co/zrZPBAjh5p
Meral K. El Ramahi, MD
Tweet
Abst#0946 shows a distinct lipid profile in RA vs PsA synovium + synovial fluid.
Sphingomyelins & phosphatidyl-cholines/ethanolamines had the greatest separation power to classify RA + PsA samples. These lipid markers may have clinical utility if validated.
#ACR21 @Rheumnow https://t.co/ktKRypTtlE
Meral K. El Ramahi, MD
Tweet
Do you use RAPID3 in PsA?
Abst#0633 at #ACR21 shows a strong agreement between RAPID3 remission score w/ DAPSA + cDAPSA, esp when redefining RAPID3 categories.
Is this practice △ing? With more studies to validate, yes, since RAPID3 is simpler!
@RheumNow https://t.co/2q0FLeBSkC https://t.co/M3WDTGzEOT
Monozygotic twin study in PsO patients showed a gut and skin microbiome difference compared to their "normal" twin
⭐️Ruminococcus decreased/absent in gut flora of PsO
⭐️microbiome differences even in healthy PsO skin
Abs#944
#ACR21
@RheumNow
#ACRBest
https://t.co/VlfVh5Kt3Y https://t.co/W0eSqi77lx
Abst0944 #ACR21 #ACRBest @RheumNow microbiom evaluation of MZ twins discordant for PSO reveals Ruminococcus bromii species significantly reduced & two pathways related to tetrahydrofolate biosynthesis upregulated in PSO twins compared to their unaffected siblings (p< 0.05) https://t.co/67ao0l23sI
Richard Conway
Tweet
Dr Exarchou presents incidence of PsA in Sweden. 22/100000. 75% received DMARDs within 2 years, which seems high, so perhaps this is tip of iceberg with milder cases undiagnosed. Abstr#0571 #ACR21 @RheumNow https://t.co/kANG6KBnOd
swethaann23
Tweet
Novel study exploring microbial differences in MZ twins discordant for psoriatic disease
⭐️Ruminococcus 🔽/❎ Gut of Ps pts and maybe associated with Ps Dis
⭐️NL skin scalp of Psoriatic pts 🔽 microbial diversity compared to unaffected twins
Abst#0944 #ACR21 #ACRBest @RheumNow
Richard Conway
Tweet
Dr Manasson presents on microbiome differences between monozygotic twins discordant for psoriatic disease. Differences seen in gut (Ruminococcus virtually absent in psoriatic) and scalp non-lesional skin microbiomes Abstr#0944 #ACR21 @RheumNow https://t.co/8Ch0M4dwUH
Eric Dein
Tweet
#ACR21 Abst#0786. Fibroscan screening for liver injury in pts on MTX:
▶️No significant correlation between cumulative MTX dose and liver stiffness by fibroscan, even at high dose MTX.
⭐️Age, sex, waist circumference, BMI are risks
@Rheumnow https://t.co/IhcNr9fhEh https://t.co/c7TUoGrNZ7
Meral K. El Ramahi, MD
Tweet
#ACR21 Abst#0449:
Ever wish you had a tool to help you predict which PsA pts will progress to radiographic damage?
➡️Proteomic approaches identified 103 candidate biomarker peptides related to 69 proteins that can potentially do so!
@Rheumnow @uptoTate
https://t.co/uUsZlBLTWC
Meral K. El Ramahi, MD
Tweet
#ACR21 Abst#0452
⭐️Total Body PET/CT (TB-PET/CT) as a tool to identify subclinical PsA at the point of transition from psoriasis (PsO).
➡️Should all pts w/ new dx of PsO have a baseline TB-PET/CT to identify early PsA?
#ACRBest @Rheumnow @uptoTate
https://t.co/IuxVuJgFSd https://t.co/AIuH9CIucy
Meral K. El Ramahi, MD
Tweet
#ACR21 Abst#0182
Does tenderness in non-swollen joints of PsA or RA pts portend inflammation & radiographic damage?
⭐️NO, except in early PsA!
➡️Abnormal PDUS associated w/ radiographic progression vs tenderness otherwise
#ACRBest @Rheumnow @uptoTate
https://t.co/iB1E0SL45e https://t.co/3Q30LeCMH4
@JointMD shares his thoughts on IL23, IL17, TNF inh- where/when/how we might use them. @RheumNow #acr21 https://t.co/mVw05iFPhF
